Obesity Clinical Trial
Official title:
Investigating the Role of Fasted Exercise on Improving Cardiometabolic Health; a Potential Mediatory Role of Sirtuins
The aim of this randomised control trial is to investigate the role of fasted exercise on cardiometabolic health. Participants will be assigned to one of three conditions, fasted exercise, fed exercise and control (no exercise). Participants in the exercise groups will complete four weeks of moderate intensity cycling exercise, three times per week, either in the fasted or fed state according to their group assignment. Experimental trials involving anthropometric and cardiometabolic disease risk factor measurements as well as metabolic responses to a subsequent meal ingestion following exercise will be compared pre-intervention and post intervention.
Status | Recruiting |
Enrollment | 30 |
Est. completion date | May 2025 |
Est. primary completion date | April 2025 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 40 Years |
Eligibility | Inclusion Criteria: - Male or female - Non-smokers - Physically inactive (partake in no more than one exercise session per week on average) - Body mass index >18.5 kg/m2 - Healthy as assessed by medical screening questionnaire - Prior recipient of local anaesthetic with no known adverse effects, no known hypersensitivity or no other health issue that may constrain the administration of lidocaine hydrochloride - Free from musculoskeletal injury and able to perform cycling exercise - Capacity to give informed consent Exclusion Criteria: - Regular exerciser - BMI < 18.5 kg/m2 - Pregnant - Allergy or intolerances to test meal products/ingredients (such as wheat or dairy products). - Recent major body weight change (+/- 3 kg in the past month) - Known hypersensitivity to Lidocaine Hydrochloride - Cardiovascular disease - complete heart block or hypovolaemia - Adam's-Stokes Syndrome - Wolff-Parkinson-White Syndrome - Porphyria - Epilepsy - Myasthenia Gravis - Other chronic medical condition or diagnosis including respiratory (eg asthma), endocrine, cardiovascular, neuromuscular disorders. - Taking medications or receiving treatment that may constrain the administration of lidocaine or local anaesthesia. |
Country | Name | City | State |
---|---|---|---|
United Kingdom | Manchester Metropolitan University | Manchester | Greater Manchester |
Lead Sponsor | Collaborator |
---|---|
Manchester Metropolitan University | European Society for Clinical Nutrition and Metabolism |
United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Changes in circulating concentrations of key metabolic markers following a high fat lunch meal | Serum concentrations of clinical chemistry blood analytes (glucose, triglycerides, cholesterol) | 9 blood samples collected at pre-meal ingestion then every 30 min after ingestion for four hours | |
Primary | Changes in circulating concentrations of key metabolic markers during the experimental trial day | Serum concentrations of clinical chemistry blood analytes (glucose, triglycerides, cholesterol) | 12 blood samples collected at 0 (baseline), 75 (pre-exercise), 125 (immediately post-exercise), 155 min (pre-meal ingestion) then every 30 min after ingestion for four hours | |
Primary | Area under the circulating concentration versus time curve (AUC) of key metabolic markers following a high fat lunch meal | Total responses of clinical chemistry blood analytes (glucose, triglycerides, cholesterol) | 4.5 hours | |
Primary | Changes in cardiovascular and metabolic disease biochemistry risk factors | Fasted serum concentrations of clinical chemistry blood analytes (glucose, blood lipids, inflammatory markers) | 4 weeks (pre and post intervention) | |
Primary | Changes in cardiovascular disease physiological risk factors | Systolic and diastolic blood pressure and calculation of mean arterial pressure using systolic and diastolic values | 4 weeks (pre and post intervention) | |
Primary | Changes in concentration of sirtuin molecules | Serum concentrations of sirtuins | 4 weeks (pre and post intervention) | |
Primary | Changes in sirtuin molecule gene expression | Adipose tissue gene expression of sirtuins | 4 weeks (pre and post intervention) | |
Primary | Changes in sirtuin molecule tissue expression | Adipose tissue expression and cellular localisation of sirtuins | 4 weeks (pre and post intervention) | |
Secondary | Changes in cardiovascular and metabolic disease anthropometric risk factors | Waist circumference, hip circumference and waist:hip ratio | 4 weeks (pre and post intervention) | |
Secondary | Change in body composition | Body fat percentage measured using bioelectrical impedance analysis | 4 weeks (pre and post intervention) | |
Secondary | Change in body mass | Body mass in kilograms | 4 weeks (pre and post intervention) | |
Secondary | Change in substrate oxidation during the experimental trial day | Carbohydrate and fat oxidation through indirect calorimetry | 17 measurements at 0 (baseline), 15 (post-breakfast meal period), 45 (30 min post-breakfast meal period), 75 (pre-exercise), every 10 min during exercise, 155 (pre-meal ingestion), then every 30 min for four hours. | |
Secondary | Heart rate response to exercise | Heart rate during exercise in the experimental trial using telemetry | At rest before exercise then every 5 min during 50 min cycle exercise | |
Secondary | Perceived exertion | Rating of perceived exertion of exercise in the experimental trial using Borg scale | Every 5 min during 50 min cycle exercise | |
Secondary | Change in physical activity levels | Physical activity energy expenditure during the intervention period | Daily for 4 weeks | |
Secondary | Change in physical activity duration | Amount of time spent performing physical activity at different intensities (low, moderate, high) during the intervention period | Daily for 4 weeks | |
Secondary | Change in energy intake | Energy intake using weighed food diary record during the intervention period | Daily for 4 weeks | |
Secondary | Change in dietary nutritional intake | Macronutrient (carbohydrate, fat, protein) composition of food intake using weighed food diary record during the intervention period | Daily for 4 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04243317 -
Feasibility of a Sleep Improvement Intervention for Weight Loss and Its Maintenance in Sleep Impaired Obese Adults
|
N/A | |
Recruiting |
NCT04101669 -
EndoBarrier System Pivotal Trial(Rev E v2)
|
N/A | |
Terminated |
NCT03772886 -
Reducing Cesarean Delivery Rate in Obese Patients Using the Peanut Ball
|
N/A | |
Completed |
NCT03640442 -
Modified Ramped Position for Intubation of Obese Females.
|
N/A | |
Completed |
NCT04506996 -
Monday-Focused Tailored Rapid Interactive Mobile Messaging for Weight Management 2
|
N/A | |
Recruiting |
NCT06019832 -
Analysis of Stem and Non-Stem Tibial Component
|
N/A | |
Active, not recruiting |
NCT05891834 -
Study of INV-202 in Patients With Obesity and Metabolic Syndrome
|
Phase 2 | |
Active, not recruiting |
NCT05275959 -
Beijing (Peking)---Myopia and Obesity Comorbidity Intervention (BMOCI)
|
N/A | |
Recruiting |
NCT04575194 -
Study of the Cardiometabolic Effects of Obesity Pharmacotherapy
|
Phase 4 | |
Completed |
NCT04513769 -
Nutritious Eating With Soul at Rare Variety Cafe
|
N/A | |
Withdrawn |
NCT03042897 -
Exercise and Diet Intervention in Promoting Weight Loss in Obese Patients With Stage I Endometrial Cancer
|
N/A | |
Completed |
NCT03644524 -
Heat Therapy and Cardiometabolic Health in Obese Women
|
N/A | |
Recruiting |
NCT05917873 -
Metabolic Effects of Four-week Lactate-ketone Ester Supplementation
|
N/A | |
Active, not recruiting |
NCT04353258 -
Research Intervention to Support Healthy Eating and Exercise
|
N/A | |
Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
Recruiting |
NCT03227575 -
Effects of Brisk Walking and Regular Intensity Exercise Interventions on Glycemic Control
|
N/A | |
Completed |
NCT01870947 -
Assisted Exercise in Obese Endometrial Cancer Patients
|
N/A | |
Recruiting |
NCT05972564 -
The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function
|
Phase 1/Phase 2 | |
Recruiting |
NCT06007404 -
Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
|
||
Recruiting |
NCT05371496 -
Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction
|
Phase 2 |